François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Using Circulating Tumor Cells to Direct Treatment
2018 San Antonio Breast Cancer SymposiumFrançois-Clément Bidard, MD, PhD, of the Institut Curie and the University of Versailles, discusses phase III study findings on the clinical utility of circulating tumor cell count as a tool to choose between first-line hormone therapy and chemotherapy for estrogen receptor–positive, HER2-negative metastatic breast cancer (Abstract GS3-07).
Related Videos
Shanu Modi, MD, on Low HER2-Expressing Breast Cancer: Updated Trial Findings
Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings from a large phase I study on trastuzumab deruxtecan in patients with low HER2-expressing breast...
Harold J. Burstein, MD, PhD, and Daniel F. Hayes, MD, on Breast Cancer With Positive Lymph Nodes: Treatment Controversy
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, and Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center debate whether all wom...
Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care
Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse ...
Shoichiro Ohtani, MD, PhD, on Extending Adjuvant Aromatase Inhibitor Therapy: Phase III Trial Results
Shoichiro Ohtani, MD, PhD, of Hiroshima City Hiroshima Citizens Hospital, discusses study findings on extending anastrozole to 10 years, which led to higher rates of disease-free s...
Allison Magnuson, DO, on Older Patients With Breast Cancer: A New Tool to Help Guide Treatment Decisions
Allison Magnuson, DO, of the University of Rochester Strong Memorial Hospital, discusses the development of a chemotherapy toxicity risk score that is associated with dose reductio...
